左心耳封堵术后卒中机制与严重程度:LAAOS III随机临床试验启示
该研究为LAAOS III随机临床试验的事后探索性分析,纳入4811例接受心脏手术的房颤患者,比较手术左心耳封堵(LAAO)加标准治疗与单纯标准治疗。首次缺血性卒中共273例,LAAO组卒中后第7天或出院时mRS评分更优(共同OR 0.80,95%CI 0.65-0.99),30天死亡率更低(16.5% vs 20.1%;HR 0.55,95%CI 0.31-0.97),皮层梗死及推测心源性栓塞性卒中比例均更低。
要点
- LAAO降低房颤心脏手术患者推测心源性栓塞性卒中比例(42.9% vs 57.9%)。
- LAAO组卒中后30天死亡率更低(16.5% vs 20.1%;HR 0.55,95%CI 0.31-0.97)。
- LAAO组卒中后第7天或出院时mRS评分更优(共同OR 0.80,95%CI 0.65-0.99)。
核心结论
- 房颤患者心脏手术中行LAAO与推测心源性栓塞性卒中风险降低、卒中后残疾减轻及死亡率降低相关。
研究设计与样本
- LAAOS III随机临床试验的事后探索性分析,纳入27国105中心2012年7月至2018年10月招募的房颤且CHA2DS2-VASc评分≥2的心脏手术患者。
- 共4811例参与者随访3.8年,其中273例发生首次缺血性卒中。
- 干预为手术LAAO加标准治疗对比单纯标准治疗。
主要发现
- 首次缺血性卒中患者平均(SD)年龄75(7)岁,女性104例(38%),男性169例(62%)。
- LAAO组卒中后第7天或出院时mRS评分降低(共同OR 0.80;95%CI 0.65-0.99)。
- LAAO组卒中后30天死亡率更低(16.5% vs 20.1%;HR 0.55;95%CI 0.31-0.97)。
- LAAO组皮层梗死比例更低(46.2% vs 61.3%;比例差-15.2%;95%CI -26.7%至-3.7%)。
- LAAO组推测心源性栓塞性卒中比例更低(42.9% vs 57.9%;比例差-15.1%;95%CI -26.5%至-3.7%)。
临床怎么用
- 对于CHA2DS2-VASc评分≥2且因其他指征接受心脏手术的房颤患者,可考虑同期行手术LAAO以降低卒中风险及减轻卒中严重程度。
局限性
- 本研究为LAAOS III的事后探索性分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Left Atrial Appendage Occlusion Study III (LAAOS III), surgical occlusion of the LAA during cardiac surgery for patients with known history of atrial fibrillation (AF) substantially reduced the risk of stroke. OBJECTIVE: To assess the impact of LAAO on ischemic stroke subtype and outcome. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc exploratory analysis of the LAAOS III randomized clinical trial. Data were adjudicated from June 28, 2023, to November 29, 2023, and the main analyses took place from December 18, 2023, to April 29, 2024. The LAAOS III trial recruited participants from 105 centers in 27 countries between July 2012 and October 2018. Patients with AF and a CHA2DS2-VASc score of at least 2 undergoing cardiac surgery for other indications were included in the analysis. INTERVENTIONS: Surgical LAAO plus standard care vs standard care alone. MAIN OUTCOMES AND MEASURES: For strokes occurring during the trial, the functional outcome as measured by the modified Rankin Scale (mRS) score at day 7 or discharge, mortality, the presence of cortical infarcts, and the occurrence of infarcts of presumed cardioembolic origin were examined. RESULTS: Of 4811 participants in the LAAOS III trial followed up for 3.8 years, 273 had a first ischemic stroke. The mean (SD) age of participants at the time of the first ischemic stroke was 75 (7) years, 104 were female (38%), and 169 were male (62%). Participants allocated to receive LAAO had reduced (common odds ratio [OR], 0.80; 95% CI, 0.65-0.99) mRS scores at 7 days or discharge and a lower risk for mortality at 30 days (16.5% vs 20.1%; hazard ratio [HR], 0.55; 95% CI, 0.31-0.97) after a stroke event. Participants allocated to LAAO had fewer cortical infarcts on neuroimaging (46.2% vs 61.3%; difference in proportions: -15.2%; 95% CI, -26.7% to -3.7%), as well as a lower proportion of ischemic strokes of presumed cardioembolic etiology when compared with ischemic strokes in the no-LAAO group (42.9% vs 57.9%; difference in proportions: -15.1%; 95% CI, -26.5% to -3.7%). CONCLUSIONS AND RELEVANCE: This study found that LAAO in patients with AF undergoing cardiac surgery was associated with a decreased risk of presumed cardioembolic stroke, reduced disability, and mortality from stroke. These findings underscore the benefit of LAAO for patients with AF undergoing cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01561651.
引用
- Katsanos AH, Whitlock RP, Belley-Côté EP, et al. Stroke Mechanism and Severity After Left Atrial Appendage Occlusion: Insights From the LAAOS III Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 41247709. doi:10.1001/jamaneurol.2025.4478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。